JP2017519821A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519821A5
JP2017519821A5 JP2017518397A JP2017518397A JP2017519821A5 JP 2017519821 A5 JP2017519821 A5 JP 2017519821A5 JP 2017518397 A JP2017518397 A JP 2017518397A JP 2017518397 A JP2017518397 A JP 2017518397A JP 2017519821 A5 JP2017519821 A5 JP 2017519821A5
Authority
JP
Japan
Prior art keywords
group
alkyl
membered
alkyl group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518397A
Other languages
English (en)
Japanese (ja)
Other versions
JP6680774B2 (ja
JP2017519821A (ja
Filing date
Publication date
Priority claimed from CN201410271282.9A external-priority patent/CN105461711B/zh
Application filed filed Critical
Priority claimed from PCT/CN2015/081518 external-priority patent/WO2015192760A1/zh
Publication of JP2017519821A publication Critical patent/JP2017519821A/ja
Publication of JP2017519821A5 publication Critical patent/JP2017519821A5/ja
Application granted granted Critical
Publication of JP6680774B2 publication Critical patent/JP6680774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518397A 2014-06-17 2015-06-16 PI3K阻害剤としてのピリド[1,2−a]ピリミドン類似体 Active JP6680774B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410271282.9A CN105461711B (zh) 2014-06-17 2014-06-17 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN201410271282.9 2014-06-17
CN201510324348 2015-06-12
CN201510324348.0 2015-06-12
PCT/CN2015/081518 WO2015192760A1 (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物

Publications (3)

Publication Number Publication Date
JP2017519821A JP2017519821A (ja) 2017-07-20
JP2017519821A5 true JP2017519821A5 (enExample) 2018-06-28
JP6680774B2 JP6680774B2 (ja) 2020-04-15

Family

ID=54934872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518397A Active JP6680774B2 (ja) 2014-06-17 2015-06-16 PI3K阻害剤としてのピリド[1,2−a]ピリミドン類似体

Country Status (11)

Country Link
US (1) US9856256B2 (enExample)
EP (1) EP3159341B8 (enExample)
JP (1) JP6680774B2 (enExample)
KR (1) KR102495840B1 (enExample)
CN (1) CN106470992B (enExample)
AU (1) AU2015276699B2 (enExample)
CA (1) CA2951971C (enExample)
EA (1) EA032642B1 (enExample)
ES (1) ES2754264T3 (enExample)
TW (1) TWI628180B (enExample)
WO (1) WO2015192760A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102731762B1 (ko) * 2015-12-16 2024-11-18 치아타이 티안큉 파마수티컬 그룹 주식회사 피리도[1,2-a]피리미돈 유사체, 이의 결정형, 이의 중간체 및 이의 제조방법
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
JP7331116B2 (ja) * 2019-01-24 2023-08-22 チアンスー アオサイカン ファーマシューティカル カンパニー,リミティド TGF-βR1キナーゼ阻害剤としての5-(4-ピリジルオキシ)ピラゾール類化合物
AU2020394867A1 (en) 2019-12-02 2022-05-26 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors
JP2023512724A (ja) * 2020-02-10 2023-03-28 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド リンパ腫の治療におけるピリド[1,2-a]ピリミジノン化合物の使用
WO2021180111A1 (zh) 2020-03-10 2021-09-16 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
AU2021344385A1 (en) 2020-09-15 2023-05-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma
WO2022121929A1 (zh) * 2020-12-08 2022-06-16 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
WO2023169488A1 (zh) * 2022-03-09 2023-09-14 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE369370T1 (de) * 2003-10-10 2007-08-15 Pfizer Prod Inc Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
JP5642963B2 (ja) * 2006-06-30 2014-12-17 スネシス ファーマシューティカルズ,インコーポレイティド ピリジノニルpdk1阻害剤
WO2009055418A1 (en) * 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
US8415376B2 (en) * 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
NZ604478A (en) * 2010-07-02 2014-12-24 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
WO2013071698A1 (zh) 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777B (zh) 2012-07-13 2016-03-02 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
BR112016029825B1 (pt) * 2014-06-17 2020-10-27 Cisen Pharmaceutical Co., Ltd. composto

Similar Documents

Publication Publication Date Title
JP2017519821A5 (enExample)
JP2017114908A5 (enExample)
JP2015516427A5 (enExample)
JP2016121196A5 (enExample)
JP2018531218A5 (enExample)
JP2016530259A5 (enExample)
JP2019526596A5 (enExample)
RU2020110780A (ru) Ингибитор fgfr и его медицинское применение
JP2014513051A5 (enExample)
JP2016540742A5 (enExample)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
RU2020131276A (ru) Терапевтические соединения и композиции
JP2016503797A5 (enExample)
JP2017526674A5 (enExample)
AR095423A1 (es) 2-azabiciclos sustituidos y su uso como moduladores del receptor de orexina
JP2015505296A5 (enExample)
JP2015520140A5 (enExample)
JP2012513416A5 (enExample)
JP2016540809A5 (enExample)
JP2016513130A5 (enExample)
JP2016540028A5 (enExample)
JP2020507589A5 (enExample)
JP2017538689A5 (enExample)
JP2015051983A5 (enExample)
JP2018197343A5 (enExample)